Pre-made Demcizumab benchmark antibody ( Whole mAb, anti-DLL4 therapeutic antibody, Anti-AOS6/delta4/hdelta2 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Demcizumab biosimilar, Whole mAb, Anti-DLL4 Antibody: Anti-AOS6/delta4/hdelta2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Demcizumab /dɛmˈsɪzʊmæb/ is a humanized monoclonal antibody which is used to treat patients with pancreatic cancer or non-small cell lung cancer. Demcizumab has completed phase 1 trials and is currently undergoing phase 2 trials. Demcizumab was developed by OncoMed Pharmaceuticals in collaboration with Celgene.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-137-1mg	1mg	3090
GMP-Bios-ab-137-10mg	10mg	Inquiry
GMP-Bios-ab-137-100mg	100mg	Inquiry
GMP-Bios-ab-137-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Demcizumab biosimilar, Whole mAb, Anti-DLL4 Antibody: Anti-AOS6/delta4/hdelta2 therapeutic antibody
INN Name	Demcizumab
Target	DLL4
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG2
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-I
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2012
Year Recommended	2013
Companies	Celgene Corporation;OncoMed Pharmaceuticals
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Colorectal cancer;Fallopian tube cancer;Non-small cell lung cancer;Ovarian cancer;Pancreatic cancer;Peritoneal cancer;Solid tumours
Development Tech	na